Head and Neck Neoplasms
Conditions
Brief summary
* To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival. * Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical and radiological) response rate and the safety of the treatment.
Interventions
3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically/cytologically confirmed, patients with stage T2b-T4N1 or TanyN2-3 undifferentiated or nonkeratinized squamous cell carcinoma of nasopharynx who are candidate for curative radiotherapy. * ECOG Performance Status is 0-1 * Weight loss within last 6 months \<10% of body weight * Acceptable haematological profile (as defined by a leukocyte count ≥ 4000/mm3, a platelet count ≥ 100.000mm3 and Hb ≥ 9g/100mL), and adequate renal function (as defined by serum creatinine ≤ 1.5mg/dl), and hepatic function (as defined by bilirubin ≤ 1.5 x maximum normal value even with hepatic metastasis; transaminases (ALT, AST) ≤ 1.5 x maximum normal value; alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone metastasis)
Exclusion criteria
* Patients with stage IVC or metastatic disease * Patients treated with chemotherapy for nasopharyngeal cancer * Patients treated with radiotherapy to head and neck region * Concomitant use of another anti-cancer therapy * Patients treated with amifostine or pilocarpine during protocol treatment. * Unstable medical condition that makes the patient unable to take part in a clinical study (congestive heart failure, serious arrhythmia, uncontrolled diabetes mellitus), history of myocardial infarction within last 6 months, massive pleural, peritoneal or pericardial effusion; or presence of serious uncontrolled infection. * Presence of other tumours different from carcinoma of the skin except melanoma and carcinoma in situ of the breast and cervix with disease free survival less than 5 years. * Pregnancy or breastfeeding. In women of childbearing potential and in men, an adequate contraceptive method must be used * Social or psychological condition that render the patient inadequate for the follow-up of the study * Contraindication for any of the study drugs (e.g. history of hypersensitivity to any of the ingredients of the study drugs) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate after neoadjuvant chemotherapy | From the start date of the treatment to the date of first documented progression of disease or at least until 2 years follow-up period |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients whose is disease controlled locally or regionally | from the start date of the treatment to the date of first documented local or regional tumor progression |
| Median length of overall survival | time interval from the date of treatment to the date of death or at least until 2 years follow-up period |
| Median length of disease free survival | time interval from the date of treatment to the date of death or at least until 2 years follow-up period |
| Percentage of alive patients without metastatis | from the start date of the treatment to the date of first documented distant metastasis |
Countries
Turkey (Türkiye)
Outcome results
None listed